It’s a decade since Crispr first hit the headlines and now the first product using the approach is on the verge of approval. By pharma standards, this is breakneck speed – but is gene editing about to hit the mainstream or will its shortcomings and regulatory caution hold it back?

There’s no shortage of opinions across the market, so we’ve spoken to some of the industry leaders to get their views on the challenges, opportunities and potential impact of gene editing. In this report, featuring interviews with Verve Therapeutics, Prime Medicine, Beam Therapeutics and more.

Download the new report to learn more about the goals – and realities – of this cutting edge part of the market.


Can the cumbersome nature of ex vivo projects be overcome?
Will the FDA seriously consider approving in vivo gene editing?
What's coming up for the next big things, such as base and prime editing?